Table 5.
Selected patents and patent applications related to biomarkers for anti-PD-1 and anti-CTLA-4 therapy
| Target | Example Patent or Application | Priority Date | Assignee | Markers | status |
|---|---|---|---|---|---|
| CTLA4 | US20100099090 | March 05, 2007 | BMS | Table 1A: 30 proteins Table 3A: 29 proteins | no EP, US abandoned |
| US8435516 | Oct 12, 2009 | Pfizer | C reactive protein | granted | |
| US20150118244 | May 10, 2012 | BMS | antibodies to each of at least two tumor associated antigens (CTAG2, SSX2, SPANXA1, NLRP4, PBK and SPANXB 1) | pending | |
| US2015118245 | May 12, 2008 | Moffitt Cancer Ctr | (a) CD8, Ki67, and eomesodermin (EOMES); (b) CD8 and EOMES; (c) CD8 and transforming growth factor beta receptor III (TGFβR3); (d) CD4 and C—C chemokine receptor type 7 (CCR7); (e) CD4, Ki67, and EOMES; (f) CD4 and CD71; (g) CD8 and CD109 | EP withdrawn, US pending | |
| PD-1 | WO2014194293 | May 30, 2013 | Amplimmune | (a) percentage of CD4+ or CD8+ T cells that are PD- 1HI cells; (b) concentration of serum lactate dehydrogenase; (c) absolute lymphocyte count; (c) frequency of CD8+ or PD-1+ tumor infiltrating lymphocytes; (e) gene expression of CD8A, FCGR3A, CTLA4, PD1, FASLG, CCL3, CXCL9, CXCL10, or GZMA in a tumor biopsy specimen | Pending |
| US20110200620 | Oct 06, 2004 | Mayo Clin | B7H1 | Pending | |
| US20150071910 | Mar 12, 2014 | Genentech | CD8A, IFN-g, EOMES, Granzyme-A, CXCL9 | Pending | |
| Both | WO2015116868 | Jan 29, 2014 | Caris Life Sciences | PD-1 or PD-L1 plus optionally, CTL4A, IDO l, COX2, CD80, CD86, CD8A, Granzyme A, Granzyme B, CD 19, CCR7, CD276, LAG-3, TIM-3, lpl9q, ABL1, AKT1, ALK, APC, AR, ATM, BRAF, BRCAl, BRCA2, cKIT, cMET, CSFIR, CTNNBl, EGFR, EGFRvIII, ER, ERBB2 (HER2), FGFRl, FGFR2, FLT3, GNA1 1, GNAQ, GNAS, HER2, HRAS, IDH1, IDH2, JAK2, KDR (VEGFR2), KRAS, MGMT, MGMT-Me, MLH1, MPL, NOTCH1, NRAS, PDGFRA, Pgp, PIK3CA, PR, PTEN, RET, RRM1, SMO, SPARC, TLE3, TOP2A, TOPOl, TP53, TS, TUBB3, VHL and more | Pending |
| EP2864790 | June 21, 2012 | Immusmol | Antibody to an enzyme or a metabolite of the kynurenine pathway according to any of the aforementioned for the diagnosis, prognosis, risk assessment and/or prediction of a neoplastic disease. | Pending | |
| WO2015077414 | Nov 20, 2013 | Dana Farber | preferably IDOl, IDO2, IDO, TDO2, TDO, or kynurenine pathway metabolite | Pending |